EGFR and breast carcinoma: Among many deregulated miRNAs in HER2-overexpressing breast cancer cells, miR-489 expression may be directly regulated by HER2 signaling since treatment with HER2/EGFR dual inhibitor lapatibnib can significantly reverse miR-489 expression status in HER2-positive breast cancer cells.